ELTP Income Statement - TTM - Elite Pharmaceuticals, Inc.

Income Statement (TTM)

Elite Pharmaceuticals, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000,000 except per share units.

	2020 09-30	2020 12-31	2021 03-31	2021 06-30	2021 09-30	2021 12-31	2022 03-31	2022 06-30	2022 09-30	2022 12-31	2023 03-31	2023 06-30	2023 09-30	2023 12-31	2024 03-31	2024 06-30	2024 09-30	2024 12-31	2025 03-31	2025 06-30
Revenue	25	26	25	25	26	29	32	33	33	33	34	35	41	47	57	66	71	70	84	105
Change (%)		3.98	-2.12	-1.90	4.65	11.24	11.30	1.91	0.08	0.85	2.92	3.83	15.71	15.31	19.67	17.35	7.11	-1.65	20.07	25.47
% of Revenue	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00

Cost Of Sales	13	13	14	12	13	16	17	18	18	17	18	18	21	26	30	36	39	39	44	47
Change (%)		3.69	0.32	-7.84	7.80	17.23	10.98	0.98	0.06	-5.84	5.67	3.16	16.28	21.71	18.06	20.15	8.17	-0.64	12.46	6.04
% of Revenue	52.09	51.95	53.24	50.02	51.53	54.30	54.14	53.65	53.64	50.08	51.42	51.08	51.33	54.18	53.45	54.73	55.27	55.84	52.30	44.20

Gross Operating Profit	12	12	12	12	13	13	15	15	15	17	17	17	20	22	26	30	32	31	40	59
Change (%)		4.28	-4.76	4.86	1.50	4.87	11.69	3.00	0.11	8.60	0.16	4.54	15.12	8.57	21.57	14.13	5.82	-2.90	29.69	46.78
% of Revenue	47.91	48.05	46.76	49.98	48.47	45.70	45.86	46.35	46.36	49.92	48.58	48.92	48.67	45.82	46.55	45.27	44.73	44.16	47.70	55.80

SG&A	4	4	3	4	4	4	4	5	5	6	5	5	5	6	7	8	8	9	9	11
Change (%)		-1.76	-4.70	5.97	3.78	2.92	18.60	14.51	5.15	9.76	-12.79	-0.91	7.42	5.46	26.07	4.72	9.81	12.31	-2.17	15.55
% of Revenue	14.29	13.50	13.14	14.20	14.08	13.03	13.88	15.60	16.39	17.84	15.11	14.42	13.39	12.25	12.90	11.51	11.80	13.48	10.98	10.11

R&D	6	6	5	5	5	5	4	4	4	5	6	6	8	8	7	8	7	8	8	7
Change (%)		4.64	-12.42	5.05	0.12	-5.38	-20.37	-6.09	1.92	16.40	37.36	3.03	21.78	-2.42	-9.32	14.82	-8.25	5.38	4.24	-6.13
% of Revenue	22.37	22.51	20.14	21.57	20.64	17.55	12.56	11.57	11.78	13.60	18.15	18.01	18.96	16.04	12.16	11.89	10.19	10.92	9.48	7.09

OpEx	23	24	23	23	24	26	27	28	28	28	30	31	36	40	46	53	57	58	63	66
Change (%)		2.91	-3.55	-2.65	4.75	8.84	5.25	2.05	1.33	0.54	6.77	2.41	15.29	13.22	13.59	16.50	5.92	2.23	8.68	5.68
% of Revenue	94.03	93.07	91.71	91.01	91.09	89.13	84.28	84.40	85.45	85.19	88.38	87.17	86.86	85.28	80.95	80.36	79.47	82.61	74.77	62.98

Operating Income	1	2	2	2	2	3	5	5	5	5	4	5	5	7	11	13	15	12	21	39
Change (%)		20.84	17.07	6.39	3.68	35.76	60.90	1.13	-6.66	2.67	-19.24	14.60	18.57	29.18	54.88	20.97	11.95	-16.67	74.15	84.11
% of Revenue	5.97	6.93	8.29	8.99	8.91	10.87	15.72	15.60	14.55	14.81	11.62	12.83	13.14	14.72	19.05	19.64	20.53	17.39	25.23	37.02

Interest Expense	-0	-0	-0	-0	-0	-0	-0	-0	-1	-1	-1	-1	-1	-1	-1	-1	-1	-1	-1	-1
Change (%)		-4.55	-16.55	-12.92	-16.22	-22.32	30.38	89.09	55.05	50.73	31.27	-8.75	-11.06	-22.26	-16.15	22.32	17.32	-5.21	-3.53	-11.89
% of Revenue	-1.31	-1.20	-1.02	-0.91	-0.73	-0.51	-0.59	-1.10	-1.71	-2.55	-3.26	-2.86	-2.20	-1.48	-1.04	-1.08	-1.19	-1.14	-0.92	-0.65

Net Income	3	7	5	6	6	6	9	7	7	7	4	4	18	16	20	20	-6	-18	-4	-11
Change (%)		147.00	-21.81	25.78	-10.70	4.75	48.63	-23.41	-4.14	10.51	-50.67	23.47	305.14	-12.71	29.29	-2.62	-132.62	181.56	-76.01	150.66
% of Revenue	10.56	25.10	20.05	25.70	21.93	20.65	27.58	20.73	19.85	21.76	10.43	12.40	43.42	32.87	35.51	29.47	-8.98	-25.70	-5.13	-10.26

Source: Capital IQ

Elite Pharmaceuticals, Inc. - Income Statement (TTM)

Income Statement (TTM)